InMed Pharmaceuticals (INM) Competitors $2.06 +0.00 (+0.19%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. MRKR, SPRB, MTVA, HCWB, IPA, CTXR, ATHA, BMRA, NERV, and ORGSShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Marker Therapeutics (MRKR), Spruce Biosciences (SPRB), MetaVia (MTVA), HCW Biologics (HCWB), ImmunoPrecise Antibodies (IPA), Citius Pharmaceuticals (CTXR), Athira Pharma (ATHA), Biomerica (BMRA), Minerva Neurosciences (NERV), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Marker Therapeutics Spruce Biosciences MetaVia HCW Biologics ImmunoPrecise Antibodies Citius Pharmaceuticals Athira Pharma Biomerica Minerva Neurosciences Orgenesis Marker Therapeutics (NASDAQ:MRKR) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability. Does the media prefer MRKR or INM? In the previous week, Marker Therapeutics had 2 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 5 mentions for Marker Therapeutics and 3 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 1.28 beat Marker Therapeutics' score of 0.35 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InMed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in MRKR or INM? 22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 14.5% of Marker Therapeutics shares are held by company insiders. Comparatively, 1.9% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher valuation and earnings, MRKR or INM? InMed Pharmaceuticals has higher revenue and earnings than Marker Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarker Therapeutics$3.31M3.98-$8.24MN/AN/AInMed Pharmaceuticals$4.83M0.52-$7.68M-$13.75-0.15 Which has more volatility and risk, MRKR or INM? Marker Therapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Does the MarketBeat Community prefer MRKR or INM? Marker Therapeutics received 66 more outperform votes than InMed Pharmaceuticals when rated by MarketBeat users. Likewise, 64.35% of users gave Marker Therapeutics an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMarker TherapeuticsOutperform Votes7464.35% Underperform Votes4135.65% InMed PharmaceuticalsOutperform Votes847.06% Underperform Votes952.94% Do analysts rate MRKR or INM? Marker Therapeutics presently has a consensus price target of $13.50, suggesting a potential upside of 997.56%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than InMed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33InMed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is MRKR or INM more profitable? InMed Pharmaceuticals has a net margin of -163.75% compared to Marker Therapeutics' net margin of -179.74%. Marker Therapeutics' return on equity of -89.63% beat InMed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Marker Therapeutics-179.74% -89.63% -71.62% InMed Pharmaceuticals -163.75%-90.74%-71.70% SummaryMarker Therapeutics beats InMed Pharmaceuticals on 13 of the 17 factors compared between the two stocks. Remove Ads Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.49M$6.86B$5.61B$7.73BDividend YieldN/A2.80%5.33%4.03%P/E Ratio-0.157.3023.5418.61Price / Sales0.52205.12368.5788.89Price / CashN/A65.6738.1734.64Price / Book0.406.166.784.10Net Income-$7.68M$142.11M$3.20B$247.18M7 Day Performance-27.58%-8.74%-5.60%-3.97%1 Month Performance-29.80%-10.41%-0.36%-6.37%1 Year Performance-71.65%-13.06%7.68%-2.04% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals1.4769 of 5 stars$2.06+0.2%N/A-71.7%$2.49M$4.83M-0.1510Short Interest ↓News CoveragePositive NewsGap UpMRKRMarker Therapeutics3.9334 of 5 stars$1.28+2.4%$13.50+954.7%-70.5%$13.71M$3.31M0.0060News CoverageGap UpSPRBSpruce Biosciences3.1678 of 5 stars$0.33-2.0%$2.50+657.8%-62.5%$13.63M$7.10M-0.3520Short Interest ↓Positive NewsGap DownMTVAMetaVia2.1654 of 5 stars$1.58+1.9%$12.00+659.5%N/A$13.61MN/A0.0010Positive NewsGap DownHCWBHCW Biologics1.4235 of 5 stars$0.30-1.2%N/A-82.9%$13.36M$3.50M-0.3040Earnings ReportUpcoming EarningsIPAImmunoPrecise Antibodies2.2776 of 5 stars$0.43+1.6%$5.00+1,062.8%-74.2%$13.36M$24.07M-0.5580Earnings ReportAnalyst ForecastShort Interest ↑Gap DownCTXRCitius Pharmaceuticals3.2769 of 5 stars$1.55+2.0%$54.50+3,416.1%-93.1%$13.32MN/A0.0020Positive NewsGap UpATHAAthira Pharma2.5131 of 5 stars$0.34+2.4%$13.83+3,968.6%-88.9%$13.27MN/A-0.1240Positive NewsBMRABiomerica0.9653 of 5 stars$0.71+3.6%N/A-30.1%$13.02M$5.58M-2.0960Positive NewsGap DownNERVMinerva Neurosciences3.8419 of 5 stars$1.85+2.8%$5.00+170.3%-29.8%$12.94MN/A-4.209Short Interest ↓ORGSOrgenesisN/A$2.69-4.0%N/AN/A$12.91M$662,000.000.00150Gap Down Remove Ads Related Companies and Tools Related Companies MRKR Alternatives SPRB Alternatives MTVA Alternatives HCWB Alternatives IPA Alternatives CTXR Alternatives ATHA Alternatives BMRA Alternatives NERV Alternatives ORGS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
